Table 3 Adjusted hazard ratios (95% confidence intervals) of selected outcomes comparing patients who switched to rivaroxaban from warfarin to warfarin-only users for the treatment of non-valvular atrial fibrillation, MarketScan, 2010–2014
|  | Rivaroxaban Switcher (n = 11,845) | Matched Warfarin User (n = 43,904) | Hazard Ratio (95% CI) a | p-value | ||||
|---|---|---|---|---|---|---|---|---|
Main outcomes | # Events | Person-years | IR (95% CI) | # Events | Person-years | IR (95% CI) | Â | Â |
 Ischemic stroke | 85 | 11,758 | 7.2 (5.8–8.9) | 278 | 40,081 | 6.9 (6.2–7.8) | 1.06 (0.83–1.36) | 0.62 |
 Intracranial bleeding | 24 | 11,808 | 2.0 (1.3–3.0) | 83 | 40,221 | 2.1 (1.7–2.5) | 1.04 (0.66–1.65) | 0.86 |
 Myocardial infarction | 77 | 11,776 | 6.5 (5.2–8.1) | 252 | 40,283 | 6.3 (5.5–7.1) | 1.08 (0.84–1.40) | 0.55 |
 Gastrointestinal bleeding | 216 | 11,681 | 18.5 (16.1–21.1) | 489 | 39,955 | 12.2 (11.2–13.4) | 1.55 (1.32–1.83) | <0.0001 |
Control outcomes | ||||||||
 Hip / pelvic fracture | 86 | 11,765 | 8.2 (6.6–9.9) | 410 | 40,091 | 10.2 (9.3–11.3) | 0.73 (0.58–0.92) | 0.009 |
 Breast / prostate cancer | 107 | 11,749 | 9.1 (7.5–11.0) | 297 | 40,164 | 7.4 (6.6–8.3) | 1.21 (0.97–1.51) | 0.10 |
 Asthma | 166 | 11,720 | 14.2 (12.1–16.4) | 482 | 40,063 | 12.0 (11.0–13.1) | 1.12 (0.94–1.34) | 0.21 |